上海，北京——2020年10月27日，维亚生物科技（上海）有限公司(以下简称“维亚生物”)与北京百奥赛图基因生物技术有限公司(以下简称“百奥赛图”)签署战略合作协议，双方将携手合作，就加速生物创新药早期研发建立战略合作关系。
本次合作将基于百奥赛图具有自主知识产权的全人抗体小鼠平台(包括RenMabTM、RenLite®、RenNano®）优势，与维亚生物全球领先的基于结构的综合性新药发现平台形成技术互补、并与其EFS（服务换股权）业务实现协同效应，共同推进生物创新药物开发。
维亚生物作为全球领先的基于结构的药物发现平台，为全球生物科技及制药客户的临床前阶段的创新药物开发提供先进的基于结构的药物发现服务，涵盖客户对早期药物发现的全方位需求。截止到2020年6月30日，维亚生物已为全球495名生物科技及制药客户提供药物发现服务，包括全球十大药企以及“Fierce Biotech 15”最具潜力生物科技公司中的29家。集团的EFS（服务换股权）业务亦向全球高潜力的生物科技初创公司提供药物发现及孵化服务，目前已累计投资孵化56家生物医药初创企业，覆盖全球多个地区，囊括多种适应症和前沿医学领域，作用机制广泛。
百奥赛图拥有基于基因编辑模式动物且高度整合的生物创新药物开发平台，凭借强大的技术创新能力，已与包括14家全球Top 20药物公司在内的2000多个合作伙伴建立了多种合作。目前已有三个合作研发的生物创新药进入I期临床，多个抗体药即将进入临床申报阶段。随着“千鼠万抗”计划的稳步进行，相信未来将有更多全人抗体药物进入临床。
“非常高兴能与维亚生物开展本次合作，”百奥赛图首席执行官沈月雷博士表示：“我们将与维亚生物一起，为具有高度创新的生物药初创企业提供多元化全方位的支持，加速创新药物研发，为更多患者提供帮助。”
维亚生物总裁任德林博士表示：“百奥赛图全人抗体小鼠平台具有的抗体编码形式与人更相近，易于免疫，兼容各种抗体筛选手段。其所得抗体多样性丰富，易于成药的特点，将有效填补维亚生物在全人抗体小鼠使用比较局限的短板，进一步提升维亚生物的吸引和孵化更多生物医药创新企业的能力，有效拓展EFS商业模式的可延展性。”
关于百奥赛图
百奥赛图是一家创新技术驱动新药研发的国际性生物技术公司，致力于成为全球新药发源地，以造福全球病患为己任。基于百奥赛图自主研发并拥有完全独立知识产权的全人抗体RenMab、RenLite、RenNano小鼠，将单细胞抗体发现技术平台、高效的基因编辑模型开发平台、规模化动物模型供应平台、快速的动物体内外药效评价平台、强大的临床开发能力有机整合在一起，形成了独具特色、涵盖药物研发全流程的新药研发体系。公司成功战略转型为Biotech，未来将更聚焦于创新抗体药物研发。随着规模化抗体药物研发-“千鼠万抗”计划的实施，百奥赛图将携手全球合作伙伴，共同加速新药研发。百奥赛图总部位于北京，在江苏海门、美国波士顿、上海等地设有分支机构，全资子公司祐和医药专注于临床开发。
更多信息，请点击：www.bbctg.com.cn
Shanghai and Beijing - Viva Biotech (Shanghai) Co., Ltd. ("Viva Biotech") and Bejing Biocytogen Co., Ltd. (“Biocytogen”) and announced today a strategic collaboration to jointly accelerate the early-stage drug discovery.
The strategic collaboration will combine Biocytogen’s fully human antibody mouse platforms (including RenMab™, RenLite®, and RenNano®) of independent proprietary intellectual property with Viva Biotech’s world-leading structure-based, integrated drug discovery platform, to achieve synergies with Viva Biotech’s EFS (Equity-for-service) business model. The collaboration will allow the two companies to jointly promote innovative biologic drug discovery and development.
Viva Biotech operates a world-leading structure-based, integrated drug discovery platform, providing structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide for their preclinical stage innovative drug development, covering the full spectrum of our customers’needs for early stage drug discovery. As of June 30th, 2020, Viva Biotech has served 495 pharmaceutical customers worldwide, including top 10 global pharmaceutical companies and 29 “Fierce Biotech 15” promising biotech companies. Our EFS business also provides drug discovery and incubation services to high potential biotech start-ups around the world. Till now, the company has incubated and invested 56 early-stage companies, covering a variety of indications and cutting-edge medical areas, with a wide range of mechanisms.
Biocytogen has established a highly integrated antibody drug discovery platform based on genetically-modified animal models. With strong technological innovation capabilities, the company has built its collaboration with more than 2,000 partners, including 14 top pharmaceutical companies worldwide. Biocytogen has so far 3 innovative biologic drugs of collaboration entered phase I clinical trials, and several antibody drugs are about to enter the clinical trial application. With the steady progress of the “Project Integrum”, it is believed that more fully human antibody drugs of the pipeline will enter clinical studies in the future.
“We are very glad to witness the collaboration between Biocytogen and Viva Biotech,” said Dr. Yuelei Shen, CEO of Biocytogen. “Along with Viva Biotech, we will provide diversified and all-round support for highly innovative biotech start-ups, accelerate the research and development of innovative drugs, and provide help for more patients.”
Dr. Delin Ren, President of Viva Biotech said, “Biocytogen's fully human antibody mouse platform has an antibody coding format that is more similar to humans, which is easy for immunization, and is compatible with various antibody screening methods. The antibodies obtained are rich in diversity and better in druggability, which will effectively fill the gaps of Viva Biotech in the use of fully human antibody mice. The collaboration will further enhance the scalability of Viva Biotech’s EFS business model, thereby strengthening its ability in attracting and incubating more innovative startups.”
